Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02158273 · ClinicalTrials.gov registry record · Phase 2

Medication Development in Alcoholism: Investigating PPAR Agonists

A Phase 2 study, sponsored by The Scripps Research Institute.

Completed
Registry status
Phase 2
Development phase
50
Enrollment target

NCT02158273: Completed Phase 2 study, sponsored by The Scripps Research Institute.

NCT02158273 is a Phase 2 study that has completed, run by The Scripps Research Institute. The registered enrollment target is 50 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (62% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02158273, a Phase 2 study, has completed, sponsored by The Scripps Research Institute.

COMPLETED
Registry status
Phase 2
Development phase
50 participants
Enrollment target

Study Summary

The primary hypotheses under test are that alcohol dependent subjects treated with fenofibrate will report decreased craving for alcohol following cue-exposure in the laboratory and report less drinking post treatment relative to placebo.

Primary Outcome

The four Visual Analog Scale (VAS) questions assess domains of alcohol craving: the intention to drink, loss of control, relief craving, and urge intensity. Each VAS scale item score ranges from 1-20 where a one indicates no craving and 20 indicates severe craving; thus, a higher score indicates a worse outcome. Total is a summation of the four VAS item scores (i.e. Intent, Impulse, Relief, Strength) and ranges in value from 4-80 with higher scores indicative of a worse outcome.

Interventions

  • DRUG Sugar Pill
  • DRUG TRICOR (fenofibrate)

Trial Details

FieldValue
Enrollment Target 50 participants
Start Date 2014-05
Est. Completion 2016-04
Phase Phase 2
The Scripps Research Institute

16 total trials

What the finished NCT02158273 record still lists

NCT02158273 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 50 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (62% lower).

The record links to 0 conditions, and to 2 interventions - of which Sugar Pill is the first listed.

NCT02158273 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT02158273 about?

NCT02158273 is a clinical study titled "Medication Development in Alcoholism: Investigating PPAR Agonists". The primary hypotheses under test are that alcohol dependent subjects treated with fenofibrate will report decreased craving for alcohol following cue-exposure in the laboratory and report less drinking post treatment relative to placebo.

What is the current status of trial NCT02158273?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 50 participants. The study started on 2014-05. Estimated completion is 2016-04.

What interventions are being tested in trial NCT02158273?

The interventions under investigation include: Sugar Pill (DRUG), TRICOR (fenofibrate) (DRUG).

Who is sponsoring clinical trial NCT02158273?

This trial is sponsored by The Scripps Research Institute, which has 16 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT02158273's enrollment target sits among peer trials

50 1195th of 2000 higher than 740 of 2,000 other Phase 2 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00200889 · 50 participants · Early Phase 1

    Mapping Auricular Vagus Nerve Circuitry

  • NCT00409435 · 50 participants · Phase 2

    A Study of Pyridostigmine in Postural Tachycardia Syndrome

  • NCT01202305 · 50 participants

    The Use of Lymph Node Biopsies to Support HIV Pathogenesis Studies

  • NCT01225913 · 50 participants · Phase 4

    Mechanism(s) of Airflow Limitation During Exacerbation of Asthma

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT02158273, the US trial registry maintained by the National Library of Medicine. NCT02158273 (small enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.